中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(9): 2120-2124

Efficacy and safety of sequential lenvatinib therapy after stereotactic body radiotherapy in treatment of advanced primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2021.09.023
  • 1.

    The Second Clinical Medical School of Southern Medical University, Beijing 100039, China

  • 2.

    Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

  • Received Date: 2021-02-01
  • Accepted Date: 2021-05-10
  • Published Date: 2021-09-20
    Abstract
  •   Objective  To investigate the efficacy and safety of sequential lenvatinib therapy after stereotactic body radiotherapy (SBRT) in the treatment of advanced primary liver cancer.  Methods  A total of 18 patients with advanced primary liver cancer who were admitted to The Fifth Medical Center of Chinese PLA General Hospital from October 2018 to May 2019 were enrolled, among whom there were 4 patients with BCLC stage B liver cancer and 14 patients with BCLC stage C liver cancer. The prescribed dose of planning target volume was 48-55 Gy (median 50 Gy) in 6-9 fractions, and the median of single dose was 6 (5-9) Gy per fraction. Oral administration of lenvatinib was given since 1 week after SBRT was finished, with a median medication time of 9.5 (3.6-25.8) months. Follow-up was performed once a month for the first 3 months after treatment and once every 3 months after 3 months of treatment. The Kaplan-Meier method was used to calculate overall survival (OS) rate, progression-free survival (PFS) rate, and local control (LC) rate, and the incidence rates of adverse reactions and complications were also observed.  Results  Up to the follow-up on November 30, 2020, a total of 8 patients died, among whom 3 died of liver failure, 3 died due to tumor progression, 1 died of perforation of gallbladder, and 1 died of gastrointestinal bleeding. At 3, 6, 9, 12, and 18 months of treatment, the OS rates were 100%, 94%, 83%, 72%, and 67%, respectively, the PFS rates were 100%, 67%, 50%, 22%, and 17%, respectively, and the LC rates were 100%, 94%, 94%, 94%, and 94%, respectively; the median OS time was > 18 months, and the median PFS time was 9 months. Of all patients, 1 (6%) had a grade 3 adverse reaction during SBRT and 2 (11%) experienced a grade 3 adverse reaction during lenvatinib treatment, and no fatal adverse reaction was observed.  Conclusion  It is preliminarily proved that sequential lenvatinib therapy after SBRT is an effective and safe treatment method for advanced primary liver cancer.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2]
    ZHENG RS, SUN KX, ZHANG SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.

    郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.
    [3]
    BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update[J]. Hepatology, 2011, 53(3): 1020-1022. DOI: 10.1002/hep.24199.
    [4]
    LAU WY, LAI EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma—a strategy to increase resectability[J]. Ann Surg Oncol, 2007, 14(12): 3301-3309. DOI: 10.1245/s10434-007-9549-7.
    [5]
    LLOVET JM, BRÚ C, BRUIX J. Prognosis of hepatocellular carcinoma: The BCLC staging classification[J]. Semin Liver Dis, 1999, 19(3): 329-338. DOI: 10.1055/s-2007-1007122.
    [6]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [7]
    TSE RV, HAWKINS M, LOCKWOOD G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 2008, 26(4): 657-664. DOI: 10.1200/JCO.2007.14.3529.
    [8]
    STERZING F, BRUNNER TB, ERNST I, et al. Stereotactic body radiotherapy for liver tumors: Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy[J]. Strahlenther Onkol, 2014, 190(10): 872-881. DOI: 10.1007/s00066-014-0714-1.
    [9]
    MÉNDEZ ROMERO A, WUNDERINK W, van OS RM, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors[J]. Int J Radiat Oncol Biol Phys, 2008, 70(5): 1447-1452. DOI: 10.1016/j.ijrobp.2007.08.058.
    [10]
    MA S, JIAO B, LIU X, et al. Approach to radiation therapy in hepatocellular carcinoma[J]. Cancer Treat Rev, 2010, 36(2): 157-163. DOI: 10.1016/j.ctrv.2009.11.008.
    [11]
    ANDOLINO DL, JOHNSON CS, MALUCCIO M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4): e447-e453. DOI: 10.1016/j.ijrobp.2011.04.011.
    [12]
    BENEDICT SH, YENICE KM, FOLLOWILL D, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101[J]. Med Phys, 2010, 37(8): 4078-4101. DOI: 10.1118/1.3438081.
    [13]
    KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [14]
    CHEN AP, SETSER A, ANADKAT MJ, et al. Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0[J]. J Am Acad Dermatol, 2012, 67(5): 1025-1039. DOI: 10.1016/j.jaad.2012.02.010.
    [15]
    PAN CC, KAVANAGH BD, DAWSON LA, et al. Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S94-S100. DOI: 10.1016/j.ijrobp.2009.06.092.
    [16]
    LENCIONI R, LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. DOI: 10.1055/s-0030-1247132.
    [17]
    SHAH C, MRAMBA LK, BISHNOI R, et al. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: Pre and post sorafenib era[J]. J Gastrointest Oncol, 2017, 8(5): 789-798. DOI: 10.21037/jgo.2017.06.16.
    [18]
    RIM CH, KIM CY, YANG DS, et al. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review[J]. Radiother Oncol, 2018, 129(1): 112-122. DOI: 10.1016/j.radonc.2017.11.013.
    [19]
    SUN J, ZHANG AM, LI WG, et al. Observation of clinical efficacy of stereotactic body radiotherapy in 28 cases of large hepatocellular carcinoma[J]. Clin J Radiat Oncol, 2019, 28(10): 749-752. DOI: 10.3760/cma.j.issn.1004-4221.2019.10.007.

    孙静, 张爱民, 李文刚, 等. 28例大肝癌立体定向放疗疗效观察[J]. 中华放射肿瘤学杂志, 2019, 28(10): 749-752. DOI: 10.3760/cma.j.issn.1004-4221.2019.10.007.
    [20]
    BRADE AM, NG S, BRIERLEY J, et al. Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2016, 94(3): 580-587. DOI: 10.1016/j.ijrobp.2015.11.048.
    [21]
    FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (803) PDF downloads(65) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return